重组人IL-24对人肺腺癌A549/DDP细胞增殖活性的影响  

Effect of recombinant human interleukiu-24 on prolifera of human lung adenocarcinoma cell line A549 /DDP

作　　者：郭锦锦[1] 王少慧[1] 孙万邦[1] 宋明英[1] 

机构地区：[1]遵义医学院珠海校区/贵州省免疫学研究生教育创新基地,珠海519041

出　　处：《中国免疫学杂志》2014年第9期1178-1181,共4页Chinese Journal of Immunology

基　　金：贵州省免疫学研究生教育创新基地重点培育项目(201101)

摘　　要：目的:探讨重组人白细胞介素24(rhIL-24)对人肺腺癌耐顺铂细胞株A549/DDP细胞的体外抑制效应;探讨rhIL-24联合顺铂体外诱导A549/DDP细胞凋亡、细胞周期的影响。方法:rhIL-24、顺铂(DDP)及rhIL-24+DDP干预A549/DDP细胞,用CCK-8法检测A549/DDP细胞增殖抑制率;用流式细胞仪检测细胞凋亡及细胞周期的变化。结果:rhIL-24联合DDP作用24 h对人肺腺癌A549/DDP细胞增殖抑制率分别为25.2%,与单独用DDP组比较P<0.05有显著性差异;流式细胞仪检测rhIL-24浓度为160 ng/ml作用24 h对人肺腺癌A549/DDP细胞凋亡率为19.0%;细胞周期检测中rhIL-24作用A549/DDP细胞24 h后G2期增多。结论:rhIL-24能抑制A549/DDP细胞增殖,对正常细胞无毒性,联合DDP组效果优于单独用药组,具有化疗增敏效应;rhIL-24能诱导A549/DDP细胞凋亡和影响细胞周期。Objective： To investigate the inhibitory effects of recombinant human interleukin-24 （rhIL-24） on human lung ade- nocarcinoma cell lines A549 in vitro, and to observe the changes in apoptosis and cell cycle. Methods： Cell proliferation was detected by CCK8 assay, and the changes in apoptosis and cell cycle of A549/DDP were detected by flow cytometry after the treatment with rhIL- 24 alone, DDP alone and rhIL-24 combined with DDP. Results： The treatment with rhIL-24 significantly inhibited the growth of human lung adenocarcinoma cell lines A549/DDP in vitro, rhIL-24 （ 160 ng/ml） combined with DDP after 24 h, resulted in a 25.2% growth inhibition,which showed a significant difference with DDP alone group. The apoptosis rate of A549/DDP detected by flow cytometry in combination group was 19% Furthermore,cell cycle detection indicated that the percentage of A549/DDP in G2 phases increased re- spectively in rhIL-24 alone group. Conclusion： The treatment with rhIL-24 led to the growth inhibition of A549/DDP, non-toxic to normal cells ,rhlL-24 combine with DDP ring about a striking effect than rhIL-24 single work. rhlL-24can enhances the effect of chemo- therapy, rhIL-24 can induce apoptosis and cell-cycle alteration of human lung adenocarcinoma A549/DDP.

关 键 词：白细胞介素24 肺腺癌 细胞耐药 生长抑制 细胞凋亡 

分 类 号：R392.5[医药卫生—免疫学] R392.11[医药卫生—基础医学]